… We wanted to compare the safety and effectiveness of oral antiplatelet therapy versus
placebo or no treatment in people with acute ischaemic stroke to see if oral antiplatelet drugs …

… potent antiplatelet agents. We focus this state-of-the-art review on the most recent advances
in oral antiplatelet therapy, … of dual antiplatelet therapy and future of personalized antiplatelet …

… coronary intervention receive antiplatelet therapy to reduce the risk … in individual responses
to oral antiplatelet therapy and its … Current guidelines recommend antiplatelet therapy with a …

Platelet-mediated thrombosis is a major pathophysiological mechanism that underlies acute
coronary syndromes, and therefore, antiplatelet therapy is an important foundation in the …

… Cangrelor, abciximab, eptifibatide, and tirofiban are intravenous antiplatelet medications.
Because these are often used together with an oral antiplatelet regimen for treating acute …

… Oral antiplatelet therapy is central to the treatment of patients with thrombotic diseases. Yet,
… This has prompted the search for more efficacious oral antiplatelet agents. Drug classes that …

… reactivity during treatment with established oral antiplatelet therapy has prompted the search
… This review highlights the rationale for important oral antiplatelet drugs in development and …

… We wanted to compare the safety and effectiveness of oral antiplatelet therapy versus placebo
or no treatment in people with acute ischaemic stroke to see if oral antiplatelet medicines …

… antiplatelet therapy combined with oral anticoagulation (target INR, 2.0 to 3.0) with the efficacy
and safety of antiplatelet therapy … therapy was not more effective than antiplatelet therapy …

… risks of current oral antiplatelet agents (aspirin, clopidogrel, and prasugrel). In addition, the
properties of and the available clinical evidence for novel oral antiplatelet agents targeting …